Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
暂无分享,去创建一个
V. Soriano | J. González-lahoz | S. Rodríguez-Nóvoa | G. González-Pardo | I. Jiménez-Nácher | L. Martín-Carbonero | P. Barreiro | J. González-Lahoz | Gema González-Pardo
[1] Cheng Cheng,et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype , 2006, Clinical pharmacology and therapeutics.
[2] V. Soriano,et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Amalio Telenti,et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. , 2005, The Journal of infectious diseases.
[4] S. Rutella,et al. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. , 2005, Journal of acquired immune deficiency syndromes.
[5] S. Spector,et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children , 2005, AIDS.
[6] C. Goujard,et al. Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir , 2005, Clinical pharmacokinetics.
[7] V. Soriano,et al. Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients , 2004, HIV clinical trials.
[8] V. Calvez,et al. Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients , 2004, Antimicrobial Agents and Chemotherapy.
[9] V. Natarajan,et al. Ritonavir Decreases the Nonrenal Clearance of Digoxin in Healthy Volunteers with Known MDR1 Genotypes , 2004, Therapeutic drug monitoring.
[10] M. Sulkowski. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] M. Bray. New data in a 200-year investigation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Schubert,et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. , 2003, European journal of medical research.
[13] Conrad C. Huang,et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. , 2003, Pharmacogenetics.
[14] C. Bellodi,et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients , 2003, AIDS.
[15] S. Chaillou,et al. Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of Ritonavir , 2002, HIV clinical trials.
[16] C. Michelet,et al. Simultaneous Quantitative Assay of Six HIV Protease Inhibitors, One Metabolite, And Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human Plasma by Isocratic Reversed-Phase Liquid Chromatography , 2002, Therapeutic drug monitoring.
[17] Jacques Fellay,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.
[18] R. Green,et al. Mechanism of indinavir-induced hyperbilirubinemia. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] W. März,et al. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. , 2000, Clinical chemistry.
[20] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[21] C. Beglinger,et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. , 1999, Biochemical pharmacology.
[22] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[23] E. Beutler,et al. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] D W Nebert,et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.
[25] B. Burchell,et al. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.
[26] D Lindhout,et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.
[27] B. Burchell,et al. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. , 1995, Life sciences.
[28] K Ueda,et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. , 1990, The Journal of biological chemistry.
[29] K. Skubitz. P-glycoprotein and multidrug resistance. , 1990, American journal of clinical pathology.
[30] I. Pastan,et al. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. , 1987, The Journal of biological chemistry.